About 10,463 results

ALLMedicine™ Osteosarcoma Center

Research & Reviews  3,940 results

Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overex...
Theranostics Li K, Sun X et. al.

May 14th, 2022 - Background: Advanced breast cancer frequently metastasizes to bone, but inhibiting tumor progression in chemotherapy may occasionally enhance tumorigenesis. Here, we employed a counterintuitive approach of overexpressing Yamanaka factors (Oct4, c-...

Fever and Systemic Inflammatory Response Syndrome After Wide Resection of Pediatric Bon...
Journal of Pediatric Orthopedics; Gallaway KE, Atadja LA et. al.

May 14th, 2022 - While postoperative fever is common and thought to be physiological, data is limited in pediatric patients with bone sarcomas. Understanding the predictive value of postoperative fever and systemic inflammatory response syndrome (SIRS) in this pop...

Directionally Sensitive Fractal Radiomics Compatible With Irregularly Shaped Magnetic R...
Journal of Magnetic Resonance Imaging : JMRI; Djuričić GJ, Ahammer H et. al.

May 14th, 2022 - Computational analysis of routinely acquired MRI has potential to improve the tumor chemoresistance prediction and to provide decision support in precision medicine, which may extend patient survival. Most radiomic analytical methods are compatibl...

The emerging role of NR2F1-AS1 in the tumorigenesis and progression of human cancer.
Pathology, Research and Practice; Luo D, Liu Y et. al.

May 14th, 2022 - Long noncoding RNAs (lncRNAs) are transcripts of more than 200 nucleotides that lack the ability to encode protein. Convincing studies have indicated that lncRNAs can act as oncogenes or tumor suppressors by regulating gene expression. The novel l...

Correlation between Patient-Derived Xenograft Modeling and Prognosis in Osteosarcoma.
Orthopaedic Surgery; Sun M, Wang Z et. al.

May 12th, 2022 - To retrospectively analyze and compare the relationship between the success rate of patient-derived xenograft (PDX) modeling of osteosarcoma and prognosis (3-year overall survival rate and disease-free survival rate) and incidence of lung metastas...

see more →

Guidelines  4 results

Assessment of resection margins in bone sarcoma treated by neoadjuvant chemotherapy: Li...
Orthopaedics & Traumatology, Surgery & Research : OTSR; Gomez-Brouchet A, Mascard E et. al.

Apr 10th, 2019 - Standardized reports are essential to meeting the bone sarcoma reference center certification requirements of the French National Cancer Institute (INCa). The usual classifications of the Musculoskeletal Tumor Society (MSTS), the American Joint Co...

ENCCA WP17-WP7 consensus paper on teenagers and young adults (TYA) with bone sarcomas.
Annals of Oncology : Official Journal of the European Soc... Wilhelm M, Dirksen U et. al.

Jun 26th, 2014 - Teenagers and young adults (TYA) cancer contributes substantially to morbidity and mortality in a population with much to offer society. TYA place distinct challenges upon cancer care services, many reporting feeling marginalized and their needs n...

Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Annals of Oncology : Official Journal of the European Soc... Bielack S, Carrle D et. al.

May 9th, 2008 - Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.|2008|Bielack S,Carrle D,Jost L, ,|diagnosis,epidemiology,pathology,therapy,therapy,diagnosis,epidemiology,pathology,therapy,

Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the ...
Pediatric Blood & Cancer; Meyer JS, Nadel HR et. al.

May 6th, 2008 - The Children's Oncology Group (COG) is a multi-institutional cooperative group dedicated to childhood cancer research that has helped to increase the survival of children with cancer through clinical trials. These clinical trials include a standar...

see more →

Drugs  40 results see all →

Clinicaltrials.gov  81 results

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

May 11th, 2022 - The investigators have recently demonstrated that argininosuccinate synthase 1 (ASS1) expression is silenced in 88% of all sarcomas (n=708), and that this loss is associated with a decreased overall survival. Using the extracellular arginine deple...

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

May 6th, 2022 - The study population is patients with advanced osteosarcoma and soft tissue sarcoma who have failed in standard chemotherapy treatment. Surufatinib 300 mg once a day (QD) will be orally administrated on a 21-day cycle. Investigators will evaluate ...

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

Apr 22nd, 2022 - PRIMARY OBJECTIVES: I. To determine progression free rate at week 12 for patients with soft tissue sarcoma (STS) treated with pazopanib (pazopanib hydrochloride) plus oral topotecan (topotecan hydrochloride). SECONDARY OBJECTIVES: I. To determine ...

18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma

Apr 21st, 2022 - Primary Objective: Demonstrate correlation of pre-post reduction in 18F-FTC-146 PET/CT with amount of post-treatment tumor necrosis in newly-diagnosed and treated osteosarcoma patients. Secondary Objective: Demonstrate correlation of pre-post redu...

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

Apr 21st, 2022 - PRIMARY OBJECTIVES: I. To determine the disease control rate in patients with completely resected recurrent osteosarcoma treated with ch14.18 (dinutuximab) in combination with sargramostim (granulocyte-macrophage colony-stimulating factor [GM-CSF]...

see more →

News  108 results

FDA Accepts NDA Resubmission for Pedmark in Prevention of Platinum-Induced Ototoxicity in Solid Tumors

Apr 28th, 2022 - The FDA has accepted for filing the new drug application (NDA) resubmission for a unique formulation of sodium thiosulfate (Pedmark) for the prevention of platinum-induced ototoxicity in patients between the ages of 1 month and 18 years who have l...

NDA Resubmitted to FDA for Pedmark in Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors

Apr 28th, 2022 - The new drug application seeking the approval of a unique formulation of sodium thiosulfate (Pedmark) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients aged 1 month to less than 18 years of age with localized, nonmeta...

Genes Related to Osteosarcoma Survival Identified

Oct 12th, 2021 - Investigators in China have identified 14 immune-related genes associated with survival in osteosarcoma. When they combined them into a risk score and added one additional factor – metastases at diagnosis – the model was an "excellent" predictor o...

Key Advances in Sarcoma Lead to More Personalized Medicine Efforts

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Soft tissue sarcoma treatments have significantly advanced within the past year with new available agents, others in the pipeline, and the continued search for biomarkers to make treatment more personalized for patients...

Intriguing Research Brings Hope to Orthopedic Oncology

Oct 6th, 2021 - R. Lor Randall, MD, FACS The orthopedic oncology community has not seen many treatment advances due to the rarity of bone cancers, but emerging research could serve as a turning point for the specialized paradigm, explained R. Lor Randall, MD, FA...

see more →

Patient Education  12 results see all →